-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FAwBFJ2B+dox9+SYZmNuc/09V12mfCguLEPb5y1s51qDFjWDCOjRhVdrhdPNHqGJ C7qYriNt/VBMTyqIAp1+oQ== 0001266375-05-000010.txt : 20051005 0001266375-05-000010.hdr.sgml : 20051005 20051005153324 ACCESSION NUMBER: 0001266375-05-000010 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20051003 FILED AS OF DATE: 20051005 DATE AS OF CHANGE: 20051005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PROGENICS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000835887 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133379479 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9147892800 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Baker Mark Robert CENTRAL INDEX KEY: 0001331438 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23143 FILM NUMBER: 051124786 BUSINESS ADDRESS: BUSINESS PHONE: 718 852-5927 MAIL ADDRESS: STREET 1: 120 STATE STREET CITY: BROOKLYN STATE: NY ZIP: 11201 4 1 edgardoc.xml PRIMARY DOCUMENT X0202 4 2005-10-03 0 0000835887 PROGENICS PHARMACEUTICALS INC PGNX 0001331438 Baker Mark Robert 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 0 1 0 0 General Counsel Common Stock 2005-10-03 4 A 0 709 24.67 A 2196 D ESPP (right to buy) 23.71 2005-10-03 4 A 0 474 0 A 2006-01-03 2006-01-03 Common Stock 474 474 D Granted under the Company's Non-Qualified Employeee Stock Purchase Plan. The option will be exercisable for that number of shares equal to the option amount (25% of the optionee's quarterly salary less $6,250) divided by the lesser of the market value of the common stock on the grant date or 85% of the market value on the day prior to the exercise date. Mark R. Baker 2005-10-05 -----END PRIVACY-ENHANCED MESSAGE-----